Cellectis S.A. (NASDAQ:CLLS) Receives $7.00 Consensus Price Target from Analysts

Cellectis S.A. (NASDAQ:CLLS) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.00.

A number of equities research analysts have weighed in on the company. Barclays initiated coverage on Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a research report on Tuesday, April 14th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after buying an additional 3,284,409 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Cellectis in the 4th quarter valued at about $15,385,000. Citadel Advisors LLC acquired a new position in Cellectis in the 3rd quarter valued at about $633,000. Marshall Wace LLP raised its stake in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 168,038 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Price Performance

CLLS opened at $2.63 on Friday. Cellectis has a one year low of $1.77 and a one year high of $5.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. The stock has a market capitalization of $263.89 million, a P/E ratio of -3.93 and a beta of 2.88. The business’s 50-day simple moving average is $3.24 and its 200-day simple moving average is $3.65.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.